AbbVie has agreed to acquire Capstan Therapeutics in a deal worth up to $2.1 billion, securing access to a phase I in vivo CAR-T therapy targeting CD19 and proprietary lipid nanoparticle delivery technology. This acquisition marks AbbVie's intensified pursuit of in vivo cell therapy strategies, which could circumvent limitations of current ex vivo CAR-T treatments for autoimmune diseases and cancer. Capstan, launched in 2022, brings a candidate earlier in development but differentiated by its in vivo approach and targeted immune engineering platform.